Equinix: Technical Set-up Looks Good

 Equinix (EQIX):

EQIX has been on BofA US 1 list for a long time. It seemed to be very expensive, finally it has come back down and I have opened a position today at $640. Actually, I wish I had picked it up yesterday.

$EQIX's Technical Set-up 

1. Trading near the bottom of the bollinger bands
2. Money Flow Indicator flashing oversold
3. RSI just coming-off of oversold territory.  
4. On-balance Volume is negative indicating oversold

Exhibit: Equinix Technical Indicators

(Source: E*Trade)

Barron's Recommends Merck, But Is it a Buy At $83.

Barron's has recommended Merck (NYSE: MRK) stating that the company does not get "enough credit". Merck is currently trading at $83.48. The price is currently hugging the upper part of the Bollinger Band. The money flow indicator is approaching over-bought territory and currently sits at 60. The MACD is flashing a buy signal. All the moving averages are currently flashing a buy. If there's any pullback, the stock may be a buy at $75 or $76.  

Exhibit: Merck May Be a Buy at $75 or $76.

 

(Source: Tradingview)

 

Exhibit: Merck Moving Averages Are Indicating a Buy

 (Source: Tradingview)

Exhibit: Merck Oscillators

 

 

(Source: Tradingview)          

Large Insider Buy at Pfizer Made Me Look At that Stock

Barron's has reported that Pfizer's Director Ronald Blaylock has made the largest open-market purchase of the stock since 2003. Mr. Blaylock paid $510,000 on August 6th for 13,000 Pfizer (NYSE: PFE) shares. The Director has paid an average price of $38.53 for the shares. The stock has been trading lower and as of Friday, August 14, 2020, it was trading at $38.06. The money flow indicator is nearing oversold territory and the MACD is flashing a sell signal. A good entry point for the stock may be around $37.70. There seems to be support for the stock at this level. If the stock breaks below $37, another entry point would be around $32.50. The stock was at that level when the money flow indicator was in oversold territory on July 24, 2020.

Exhibit: Entry Points for Pfizer 

 

 (Source: Tradingview)